In a similar study, Sarangthem et al. [54] evaluated the antitumor effect of double therapeutic peptide-ELP conjugate by developing a chimeric polypeptide composed of interleukin-4 receptor-targeting peptide (AP1), the proapoptotic peptide (KLAKLAK) and ELPs for targeted treatment of glioblastoma tumors. The gene discussed is NR5A1; the disease is glioblastoma.